Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jul;27(7):493-503.
doi: 10.1007/s40263-013-0068-8.

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic

Sha Mi  1 , R Blake Pepinsky, Diego Cadavid
Affiliations
Review

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic

Sha Mi et al. CNS Drugs. 2013 Jul.

Abstract

LINGO-1 is a leucine-rich repeat and Ig domain-containing, Nogo receptor interacting protein, selectively expressed in the CNS on both oligodendrocytes and neurons. Its expression is developmentally regulated, and is upregulated in CNS diseases and injury. In animal models, LINGO-1 expression is upregulated in rat spinal cord injury, experimental autoimmune encephalomyelitis, 6-hydroxydopamine neurotoxic lesions and glaucoma models. In humans, LINGO-1 expression is increased in oligodendrocyte progenitor cells from demyelinated white matter of multiple sclerosis post-mortem samples, and in dopaminergic neurons from Parkinson's disease brains. LINGO-1 negatively regulates oligodendrocyte differentiation and myelination, neuronal survival and axonal regeneration by activating ras homolog gene family member A (RhoA) and inhibiting protein kinase B (Akt) phosphorylation signalling pathways. Across diverse animal CNS disease models, targeted LINGO-1 inhibition promotes neuron and oligodendrocyte survival, axon regeneration, oligodendrocyte differentiation, remyelination and functional recovery. The targeted inhibition of LINGO-1 function presents a novel therapeutic approach for the treatment of CNS diseases.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mov Disord. 2006 Feb;21(2):136-41 - PubMed
    1. Ann Neurol. 2009 Mar;65(3):304-15 - PubMed
    1. J Neurosci. 2007 Jan 3;27(1):220-5 - PubMed
    1. Retina. 2005 Dec;25(8 Suppl):S25-S26 - PubMed
    1. Rev Med Univ Navarra. 1997 Jul-Sep;41(3):180-4 - PubMed

MeSH terms